Selected research
Industry Research
GLP-1 Weight Loss Injection Industry Research Report 2026
Market perspective
The global GLP-1 Weight Loss Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for GLP-1 Weight Loss Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for GLP-1 Weight Loss Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for GLP-1 Weight Loss Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of GLP-1 Weight Loss Injection include Novo Nordisk, Imeik, Borui Pharmaceuticals, Gan & Lee Pharmaceuticals, Hansoh Pharmaceuticals, Hengrui Medicine, Huadong Medicine, Eli Lilly and Shanghai Benemae Biopharmaceuticals Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global GLP-1 Weight Loss Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
GLP-1 Weight Loss Injection Market by Company
Novo Nordisk
Imeik
Borui Pharmaceuticals
Gan & Lee Pharmaceuticals
Hansoh Pharmaceuticals
Hengrui Medicine
Huadong Medicine
Eli Lilly
Shanghai Benemae Biopharmaceuticals Co., Ltd.
CSPC Pharmaceutical Group
Sihuan Pharmaceuticals
Wanbang Biopharma
Innovent Biologics
GLP-1 Weight Loss Injection Segment by Type
Tirzepatide
Semaglutide
Liraglutide
Benaglutide
Others
GLP-1 Weight Loss Injection Segment by Application
Hospital
Clinic
Others
GLP-1 Weight Loss Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Weight Loss Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Weight Loss Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Weight Loss Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of GLP-1 Weight Loss Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of GLP-1 Weight Loss Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of GLP-1 Weight Loss Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tirzepatide
- Semaglutide
- Liraglutide
- Benaglutide
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Novo Nordisk
- Imeik
- Borui Pharmaceuticals
- Gan & Lee Pharmaceuticals
- Hansoh Pharmaceuticals
- Hengrui Medicine
- Huadong Medicine
- Eli Lilly
- Shanghai Benemae Biopharmaceuticals Co., Ltd.
- CSPC Pharmaceutical Group
- Sihuan Pharmaceuticals
- Wanbang Biopharma
- Innovent Biologics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global GLP-1 Weight Loss Injection Market Size (2021-2032)
- 2.2.2 Global GLP-1 Weight Loss Injection Sales (2021-2032)
- 2.2.3 Global GLP-1 Weight Loss Injection Market Average Price (2021-2032)
- 2.3 GLP-1 Weight Loss Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tirzepatide
- 2.3.3 Semaglutide
- 2.3.4 Liraglutide
- 2.3.5 Benaglutide
- 2.3.6 Others
- 2.4 GLP-1 Weight Loss Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global GLP-1 Weight Loss Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global GLP-1 Weight Loss Injection Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global GLP-1 Weight Loss Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global GLP-1 Weight Loss Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global GLP-1 Weight Loss Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of GLP-1 Weight Loss Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of GLP-1 Weight Loss Injection, Product Type & Application
- 3.8 Global Manufacturers of GLP-1 Weight Loss Injection, Established Date
- 3.9 Global GLP-1 Weight Loss Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novo Nordisk
- 4.1.1 Novo Nordisk Company Information
- 4.1.2 Novo Nordisk Business Overview
- 4.1.3 Novo Nordisk GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novo Nordisk GLP-1 Weight Loss Injection Product Portfolio
- 4.1.5 Novo Nordisk Recent Developments
- 4.2 Imeik
- 4.2.1 Imeik Company Information
- 4.2.2 Imeik Business Overview
- 4.2.3 Imeik GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Imeik GLP-1 Weight Loss Injection Product Portfolio
- 4.2.5 Imeik Recent Developments
- 4.3 Borui Pharmaceuticals
- 4.3.1 Borui Pharmaceuticals Company Information
- 4.3.2 Borui Pharmaceuticals Business Overview
- 4.3.3 Borui Pharmaceuticals GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Borui Pharmaceuticals GLP-1 Weight Loss Injection Product Portfolio
- 4.3.5 Borui Pharmaceuticals Recent Developments
- 4.4 Gan & Lee Pharmaceuticals
- 4.4.1 Gan & Lee Pharmaceuticals Company Information
- 4.4.2 Gan & Lee Pharmaceuticals Business Overview
- 4.4.3 Gan & Lee Pharmaceuticals GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gan & Lee Pharmaceuticals GLP-1 Weight Loss Injection Product Portfolio
- 4.4.5 Gan & Lee Pharmaceuticals Recent Developments
- 4.5 Hansoh Pharmaceuticals
- 4.5.1 Hansoh Pharmaceuticals Company Information
- 4.5.2 Hansoh Pharmaceuticals Business Overview
- 4.5.3 Hansoh Pharmaceuticals GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hansoh Pharmaceuticals GLP-1 Weight Loss Injection Product Portfolio
- 4.5.5 Hansoh Pharmaceuticals Recent Developments
- 4.6 Hengrui Medicine
- 4.6.1 Hengrui Medicine Company Information
- 4.6.2 Hengrui Medicine Business Overview
- 4.6.3 Hengrui Medicine GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hengrui Medicine GLP-1 Weight Loss Injection Product Portfolio
- 4.6.5 Hengrui Medicine Recent Developments
- 4.7 Huadong Medicine
- 4.7.1 Huadong Medicine Company Information
- 4.7.2 Huadong Medicine Business Overview
- 4.7.3 Huadong Medicine GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Huadong Medicine GLP-1 Weight Loss Injection Product Portfolio
- 4.7.5 Huadong Medicine Recent Developments
- 4.8 Eli Lilly
- 4.8.1 Eli Lilly Company Information
- 4.8.2 Eli Lilly Business Overview
- 4.8.3 Eli Lilly GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly GLP-1 Weight Loss Injection Product Portfolio
- 4.8.5 Eli Lilly Recent Developments
- 4.9 Shanghai Benemae Biopharmaceuticals Co., Ltd.
- 4.9.1 Shanghai Benemae Biopharmaceuticals Co., Ltd. Company Information
- 4.9.2 Shanghai Benemae Biopharmaceuticals Co., Ltd. Business Overview
- 4.9.3 Shanghai Benemae Biopharmaceuticals Co., Ltd. GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Shanghai Benemae Biopharmaceuticals Co., Ltd. GLP-1 Weight Loss Injection Product Portfolio
- 4.9.5 Shanghai Benemae Biopharmaceuticals Co., Ltd. Recent Developments
- 4.10 CSPC Pharmaceutical Group
- 4.10.1 CSPC Pharmaceutical Group Company Information
- 4.10.2 CSPC Pharmaceutical Group Business Overview
- 4.10.3 CSPC Pharmaceutical Group GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 CSPC Pharmaceutical Group GLP-1 Weight Loss Injection Product Portfolio
- 4.10.5 CSPC Pharmaceutical Group Recent Developments
- 4.11 Sihuan Pharmaceuticals
- 4.11.1 Sihuan Pharmaceuticals Company Information
- 4.11.2 Sihuan Pharmaceuticals Business Overview
- 4.11.3 Sihuan Pharmaceuticals GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sihuan Pharmaceuticals GLP-1 Weight Loss Injection Product Portfolio
- 4.11.5 Sihuan Pharmaceuticals Recent Developments
- 4.12 Wanbang Biopharma
- 4.12.1 Wanbang Biopharma Company Information
- 4.12.2 Wanbang Biopharma Business Overview
- 4.12.3 Wanbang Biopharma GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Wanbang Biopharma GLP-1 Weight Loss Injection Product Portfolio
- 4.12.5 Wanbang Biopharma Recent Developments
- 4.13 Innovent Biologics
- 4.13.1 Innovent Biologics Company Information
- 4.13.2 Innovent Biologics Business Overview
- 4.13.3 Innovent Biologics GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Innovent Biologics GLP-1 Weight Loss Injection Product Portfolio
- 4.13.5 Innovent Biologics Recent Developments
5 Global GLP-1 Weight Loss Injection Market Scenario by Region
- 5.1 Global GLP-1 Weight Loss Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global GLP-1 Weight Loss Injection Sales by Region: 2021-2032
- 5.2.1 Global GLP-1 Weight Loss Injection Sales by Region: 2021-2026
- 5.2.2 Global GLP-1 Weight Loss Injection Sales by Region: 2027-2032
- 5.3 Global GLP-1 Weight Loss Injection Revenue by Region: 2021-2032
- 5.3.1 Global GLP-1 Weight Loss Injection Revenue by Region: 2021-2026
- 5.3.2 Global GLP-1 Weight Loss Injection Revenue by Region: 2027-2032
- 5.4 North America GLP-1 Weight Loss Injection Market Facts & Figures by Country
- 5.4.1 North America GLP-1 Weight Loss Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America GLP-1 Weight Loss Injection Sales by Country (2021-2032)
- 5.4.3 North America GLP-1 Weight Loss Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe GLP-1 Weight Loss Injection Market Facts & Figures by Country
- 5.5.1 Europe GLP-1 Weight Loss Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe GLP-1 Weight Loss Injection Sales by Country (2021-2032)
- 5.5.3 Europe GLP-1 Weight Loss Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific GLP-1 Weight Loss Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific GLP-1 Weight Loss Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific GLP-1 Weight Loss Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific GLP-1 Weight Loss Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America GLP-1 Weight Loss Injection Market Facts & Figures by Country
- 5.7.1 South America GLP-1 Weight Loss Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America GLP-1 Weight Loss Injection Sales by Country (2021-2032)
- 5.7.3 South America GLP-1 Weight Loss Injection Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa GLP-1 Weight Loss Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa GLP-1 Weight Loss Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa GLP-1 Weight Loss Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa GLP-1 Weight Loss Injection Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global GLP-1 Weight Loss Injection Sales by Type (2021-2032)
- 6.1.1 Global GLP-1 Weight Loss Injection Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global GLP-1 Weight Loss Injection Sales Market Share by Type (2021-2032)
- 6.2 Global GLP-1 Weight Loss Injection Revenue by Type (2021-2032)
- 6.2.1 Global GLP-1 Weight Loss Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global GLP-1 Weight Loss Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global GLP-1 Weight Loss Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global GLP-1 Weight Loss Injection Sales by Application (2021-2032)
- 7.1.1 Global GLP-1 Weight Loss Injection Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global GLP-1 Weight Loss Injection Sales Market Share by Application (2021-2032)
- 7.2 Global GLP-1 Weight Loss Injection Revenue by Application (2021-2032)
- 7.2.1 Global GLP-1 Weight Loss Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global GLP-1 Weight Loss Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global GLP-1 Weight Loss Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 GLP-1 Weight Loss Injection Value Chain Analysis
- 8.1.1 GLP-1 Weight Loss Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 GLP-1 Weight Loss Injection Production Mode & Process
- 8.2 GLP-1 Weight Loss Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 GLP-1 Weight Loss Injection Distributors
- 8.2.3 GLP-1 Weight Loss Injection Customers
9 Global GLP-1 Weight Loss Injection Analyzing Market Dynamics
- 9.1 GLP-1 Weight Loss Injection Industry Trends
- 9.2 GLP-1 Weight Loss Injection Industry Drivers
- 9.3 GLP-1 Weight Loss Injection Industry Opportunities and Challenges
- 9.4 GLP-1 Weight Loss Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst